ViiV Heathcare Highlights Positive, 48-Week Data from ATLAS & FLAIR Pivotal Phase III Studies of Cabotegravir and Rilpivirine in Adults Living with HIV-1 Infection
Go back to ViiV Heathcare Highlights Positive, 48-Week Data from ATLAS & FLAIR Pivotal Phase III Studies of Cabotegravir and Rilpivirine in Adults Living with HIV-1 Infection| Pfizer Inc. (NYSE: PFE) | Delayed: 25.94 +0.55 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.39 | 52 Week High | $37.39 | |||
| Open | $25.39 | 52 Week Low | $28.25 | |||
| Day High | $25.95 | P/E | 15.72 | |||
| Day Low | $25.35 | EPS | $1.65 | |||
| Volume | 23,362,199 | |||||
